1. H1 2025 Financial Performance: Back in the Black

Dongkook Life Science reported KRW 69.9 billion in revenue for the first half of 2025, with Q2 revenue reaching KRW 34.8 billion, marking a successful return to profitability. The continued growth of the contrast media division and the strong performance of the MEMD division contributed significantly to this positive outcome.

2. Core Business Analysis: Synergy between Contrast Media and MEMD

2.1 Contrast Media Division: A market leader in Korea, Dongkook boasts a robust position in the contrast media landscape. With a diversified product portfolio, including ‘Duoray’, the company leverages vertical integration from API to finished products to maintain a competitive edge.

2.2 MEMD Division: Capitalizing on the synergy with its contrast media business, Dongkook is expanding its medical equipment and device distribution and sales. The company is also actively adopting advanced technologies, including AI-based image analysis software.

3. Future Growth Drivers: New Drug Development and Global Expansion

Dongkook is actively investing in new ventures, including the development of a novel MRI contrast agent and expansion into the liver cancer diagnostic market. With EU GMP and Japanese Ministry of Health, Labour and Welfare approvals, the company is laying the groundwork for global expansion.

4. Investment Strategy: Hold and Gradually Increase Holdings

Dongkook Life Science presents a compelling investment opportunity, underpinned by a solid business foundation and future growth potential. While the current recommendation is to ‘Hold’, a gradual increase in holdings can be considered based on future earnings announcements and market conditions. Investors should closely monitor risk factors, such as the aftermath of the API manufacturing suspension, intensifying competition, and foreign exchange fluctuations.

5. Key Investment Highlights

  • • Strong foundation in contrast media and MEMD expansion
  • • Promising new drug development and global market entry strategy
  • • Return to profitability and improving profitability trend